Apex BiotechnologyTPE:1733 -0.17%81 FCF Margin % is 17.27% as of Dec. 2025, which is 84% above its 10-year median of 9.41. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Apex Biotechnology ranks better than 80.68% on this metric.
The historical rank and industry rank for Apex Biotechnology's FCF Margin % or its related term are showing as below:
TPE:1733'
s FCF Margin % Range Over the Past 10 Years
Min: -0.61 Med: 9.41 Max: 18.45
Current: 7.24
During the past 13 years, the highest FCF Margin % of Apex Biotechnology was 18.45%. The lowest was -0.61%. And the median was 9.41%.
TPE:1733's FCF Margin % is ranked better than 80.68% of 947
companies
in the Biotechnology industry
Industry Median: -82.65
vs TPE:1733: 7.24
Apex Biotechnology FCF Margin % Related Terms
Apex Biotechnology FCF Margin % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Apex Biotechnology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a FCF Margin % of 17.27% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Apex Biotechnology and its competitors. This is 84% above median its historical median of 9.41. According to the industry distribution chart, Apex Biotechnology ranks #183 out of 947 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Apex Biotechnology's FCF Margin % too high?
Apex Biotechnology's current FCF Margin % of 17.27% is 84% above median its 10-year median of 9.41. Based on the distribution chart, Apex Biotechnology ranks #183 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #183 out of 947 companies for FCF Margin %. This places Apex Biotechnology in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current FCF Margin % is 17.27%, which is 84% above median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current FCF Margin % is 17.27%, which is 84% above median its 10-year median of 9.41. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current FCF Margin % is 17.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
FCF Margin %: 17.27% (84% above median its 10-year median of 9.41)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
